4-ethyl-hexan-2-one | 6022-26-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-ethyl-hexan-2-one
• 英文别名: Methyl-(β-aethyl-butyl)-keton；4-Aethyl-hexan-2-on；4-Ethyl-2-hexanone；4-ethylhexan-2-one
• CAS: 6022-26-0
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: QKMFSGUNPGTQPT-UHFFFAOYSA-N

物化性质

• 沸点：
  60 °C(Press: 18 Torr)
• 密度：
  0.811±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-ethyl-hexan-2-one 、 氰乙酸 生成 5-ethyl-2-methyl-heptanenitrile
  参考文献：
  名称：

  Rouillier,P. et al., Bulletin de la Societe Chimique de France, 1966, p. 689 - 697

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-diethyloxan-4-one 在 Rh on carbon 作用下， 以75%的产率得到4-ethyl-hexan-2-one
  参考文献：
  名称：

  Transformations of 2,2-dialkyl-4-pyranones in the vapor phase

  摘要：

  DOI：

  10.1007/bf00949747

文献信息

• 24-homo vitamin D derivatives, process for their production and
  申请人：Schering Aktiengesellschaft

  公开号：US05665716A1

  公开（公告）日：1997-09-09

  New 24-homo vitamin D derivatives of formula I ##STR1## are described, in which R.sup.1 means a hydrogen atom, a hydroxy, an alkanoyloxy group with 1 to 8 carbon atoms or an aralkanoyloxy group with up to 8 carbon atoms, R.sup.2 and R.sup.3, independently of one another, mean a linear or branched alkyl group with 1 to 4 carbon atoms, a trifluoromethyl group or together mean a saturated carbocyclic ring with 3 to 9 carbon atoms formed with carbon atom 25, R.sup.4 and R.sup.5, independently of one another, mean a hydrogen atom, an alkanoyl group with 1 to 8 carbon atoms or an aralkanoyl group with up to 8 carbon atoms, and A and B each mean a hydrogen or together a second bond, and n stands for 1, 2, 3,4 or 5.

  描述了一种公式I的新24-羟基维生素D衍生物，其中R.sup.1表示氢原子，羟基，具有1至8个碳原子的烷酰氧基团或具有多达8个碳原子的芳基烷酰氧基团，R.sup.2和R.sup.3彼此独立地表示具有1至4个碳原子的直链或支链烷基团，三氟甲基基团或者一起表示与碳原子25形成的具有3至9个碳原子的饱和碳环，R.sup.4和R.sup.5彼此独立地表示氢原子，具有1至8个碳原子的烷酰基团或具有多达8个碳原子的芳基烷酰基团，A和B各自表示氢或一起表示第二键，n代表1、2、3、4或5。
• Macromolecular Compounds Having Controlled Stoichiometry
  申请人：Krippner Guy Yeoman

  公开号：US20090118467A1

  公开（公告）日：2009-05-07

  The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

  以下发明涉及具有可控化学计量和拓扑结构的高分子，其生产过程以及其使用的应用。这些高分子具有可控的功能基团化学计量，并包括至少一个树枝状基序，其表面层由至少一个表面构建单元形成，而至少一个次表面层由至少一个构建单元形成，表面构建单元和构建单元具有一个碳氢骨架，带有一个羰基基团和至少一个胺基团；以及构建单元和/或表面构建单元上至少两种不同的功能基团；其中功能基团化学计量指的是功能基团的数量和类型。
• PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：BARTBERGER Michael David

  公开号：US20110319378A1

  公开（公告）日：2011-12-29

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了公式I的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY
  申请人：Krippner Guy Yeoman

  公开号：US20120302730A1

  公开（公告）日：2012-11-29

  The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

  以下发明涉及具有控制的化学计量和拓扑结构的大分子，其生产过程以及其使用的应用。这些大分子具有受控的功能基团化学计量，并且包括至少一个树枝状基元，其表面层由至少一个表面构建单元形成，而至少一个亚表面层由至少一个构建单元形成，表面构建单元和构建单元具有带有羰基和至少一个胺基的碳氢骨架；以及在构建单元和/或表面构建单元上至少两种不同的功能基团；其中功能基团化学计量指的是功能基团的数量和类型。
• NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：US20140336137A1

  公开（公告）日：2014-11-13

  The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

  本发明涉及一种硝基酰衍生物，包括羟基硝基化合物的羧酸和磷酸酯，其在生理条件下捐赠亚硝基（HNO）。本发明的化合物和组合物在治疗和/或预防对亚硝基治疗有反应的疾病或病情的发生和/或发展方面具有用途，包括心力衰竭，缺血/再灌注损伤和癌症。